Pneumococcal vaccination. Controversies and opportunities.
Pneumococcal vaccination. Controversies and opportunities.
复制标题
肺炎球菌疫苗接种。
DOI：
--
复制
发表时间：
1990
影响因子：
4.4
通讯作者：
Facklam Rr
中科院分区：
文献类型：
--
作者：
J. Spika;Fedson Ds;Facklam Rr
在许多高危人群中，通过接种23价肺炎球菌疫苗可以预防肺炎球菌感染相关的发病率和死亡率。虽然目前疫苗的临床效果不太理想，但使用疫苗具有成本效益。尽管建议对老年人和其他高危人群进行肺炎球菌疫苗接种，并且联邦对参加医疗保险的人进行疫苗接种报销，但据估计，1985年只有10%至15%的目标人群接种了疫苗。用肺炎球菌疫苗免疫高危人群的策略需要医生、公共卫生专业人员、健康倡导团体和目标人群的参与。
The morbidity and mortality associated with pneumococcal infections are preventable in many high-risk individuals by immunization with 23-valent pneumococcal vaccine. While the clinical effectiveness of the current vaccine is less than ideal, use of the vaccine is cost effective. In spite of recommendations for pneumococcal vaccination of elderly and other high-risk persons, and federal reimbursement for vaccination Medicare enrollees, it was estimated in 1985 that only 10% to 15% of this target population was immunized. Strategies for immunizing high-risk individuals with pneumococcal vaccine need to involve physicians, public health professionals, health advocacy groups, and persons in the targeted populations.